For HIV-1–negative, at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1. See full Indication.
APRETUDE must be administered by a healthcare provider (HCP). Prior to prescribing HCP-administered APRETUDE, HCPs should carefully select individuals who agree to the required dosing and testing schedule and counsel patients on the importance of adherence to help reduce the risk of HIV-1 infection and development of resistance.
Dosing and Testing Schedule
Adherence you can confirm with as few as 6 in-office injections per year*
Starting Your Patients on APRETUDE†
Optional oral lead-in
Oral lead-in is not required but may be used prior to the initiation of APRETUDE to assess the tolerability of cabotegravir.
The recommended oral lead-in dose is one 30-mg tablet of cabotegravir daily for approximately 1 month (at least 28 days).
Initiation injections should be administered on the last day of oral lead-in, if used, or within 3 days thereafter.
HIV-1 testing and APRETUDE
-
HIV-1 testing should also occur: - Upon diagnosis of any other STI
- When recent exposure to HIV is suspected or clinical symptoms consistent with HIV-1 (eg, fever, fatigue, myalgia, skin rash) are present
- If positive HIV-1 status is confirmed, transition to a complete HIV-1 treatment
FDA=US Food and Drug Administration; PrEP=pre-exposure prophylaxis; STI=sexually transmitted infection.
Use this tool to determine your patient’s APRETUDE injection schedule
You will be able to select a target initiation date and view your patient’s potential schedule, including subsequent injection dates and flexible dosing window
Missed Injections
Continuing APRETUDE after planned missed injections
How much time has passed since your patient’s missed Target Injection Date?
§For oral PrEP durations greater than 2 months, an alternative oral regimen is recommended.
Continuing APRETUDE after unplanned missed injections
How much time has passed since your patient’s missed Target Injection Date?
Drug Interactions
Recommendations are based on either drug interaction trials following oral administration of cabotegravir or predicted interactions due to the expected magnitude of the interaction. This chart includes potentially significant interactions but is not all inclusive.
↑ = Increase, ↓ = Decrease, ↔︎ = No Change
Dosing and Administration Guide
Download this guide to receive information on:
- APRETUDE dosing kits and storage
- The APRETUDE dosing schedule
- Administering the initiation and continuation injections
- Managing missed injections
- Injection considerations to share with your patients
Reference:
- Dept of Labor, Dept of Health and Human Services (HHS), the Treasury. FAQs About Affordable Care Act Implementation Part 47. July 19, 2021. https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-47.pdf
Reference:
- Dept of Labor, Dept of Health and Human Services (HHS), the Treasury. FAQs About Affordable Care Act Implementation Part 47. July 19, 2021. https://www.dol.gov/sites/
dolgov/files/EBSA/about-
ebsa/our-activities/resource-
center/faqs/aca-part-47.pdf
CBTWCNT230021